2/n Temporal distribution of B.1.1.7 cases doesn't accurately reflect the growth of B.1.1.7 in CT as the sequence reporting is still lagging. Next week we'll have temporal est of frequency based on SGTF. B.1.1.7 is currently associated with 5-10% of the COVID-19 cases in CT.
3/n Phylogenetics of B.1.1.7 cases show many different clusters, some associated with NY.
4/n While B.1.1.7 transmission is firmly established in CT, overall transmission of SARSCoV2 continues to decline. Shown by wastewater and cases (New Haven). As B.1.1.7 becomes more dominant, it *may* reverse this trend.
5/n We've detected 7 cases of B.1.429 in CT (first detected in California). This is not yet an official variant of concern, but it is one of many that we are watching. Much more research is needed to back up some of the claims about B.1.429.
6/n We've detected 2 lineages in CT with the E484K mutation - B.1.525 (8 cases) and the now infamous B.1.526 "New York variant" (11 cases). The concern is that E484K *may* decrease vaccine efficacy, but we really don't know what if does on these lineages. MUCH more data needed.
New SARS-CoV-2 variant update for Connecticut.
- 42 cases of B.1.1.7
- 1 case of B.1.351
- 5 cases of B.1.525 (not of concern yet, but we are monitoring)
🧬Latest #SARSCoV2 B.1.1.7 update from Connecticut.
- 9 B.1.1.7 cases detected in CT
- Most travel related
- We sequenced 28 SGTF samples from CT, 5 (18%) are B.1.1.7.
2/4 We sequenced 5 B117 cases in CT all (all in New Haven County, where we do most of our surveillance). The other four have been reported by The Jackson Labs (3, sequences not yet available) and Quest Diagnostics (1). They represent at least 4 seperate introductions.
3/4 We also sequenced 39 SGTF samples from out of state: FL, TX, TN, AZ, NJ, MA, NY, and IL. Combined with 28 form CT:
- 20 (30%) are B.1.1.7
- 40 (60%) are B.1.375
- 7 (10%) are other lineages
We'll break these down by date/location as we collect more data.
⚡️Our multiplex PCR assay has been updated to detect #SARSCOV2 variants B.1.1.7, B.1.351, and P.1 by targeting 2 deletions:
-ORF1a 3575-3677
-spike 69-70.
Preprint submission later today, short 🧵 for now 1/n
Brief update on TaqPath N gene target failure (NGTF). We believe that it is caused by a 6nt deletion (positions 28914-28919; N:214/215del) that has emerged independently at least 3 times in the US.
The @yalepathology clinical diagnostic lab recently detected 8 NGTFs from a related cluster of cases. We have so far sequenced 2 of these (Yale-S047 & Yale-S048) & they do not cluster with other N:214/215del seqs. Rather looks like it emerged within a local lineage (B.1.1.107).
33 N:214/215del seqs are located in the Pango lineage B.1.3, and have been detected in New York and Maryland.
Please let us know if you try it, and if you wouldn't mind, share your results. We just ordered the primers and will test next week, but we don't have any B.1.1.7 viruses to test. Will make protocol adjustments as we go, and will post a final version on protocols.io
No doubt many of you heard of it, either on this platform, or on the news. It generated a lot of buzz in the media, and not all of it is true. Lets walk through these, and how to get it set up in your lab.
2/n We apologize for the delay in getting information out on this. The FDA issued our EUA on a Saturday, and a media onslaught came before we could get ahead of it. This received much more attention than we ever imagined! We are working through our hundreds of emails...
3/n: Our mission is to remove capitalism from surveillance. We want to make available cheaper tests, and we believe that companies shouldn't overly profit from this. That is why we offer our protocol for free, and we are working with labs to implement cost and time saving steps.